Oxytocin Acetate
Oxytocin acetate is a synthetic nonapeptide identical to the endogenous hypothalamic neuropeptide, studied in social-behavior and neuroendocrine research models.
We have not published an audit on Oxytocin Acetate. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Physiological Roles Approved Therapeutic [Source: Peptide Protocol Wiki]
Oxytocin is a small brain-made hormone that triggers uterine contractions and milk release when it enters the bloodstream, and may influence social behavior and mood when it acts inside the brain, though getting it into the brain from a nasal spray or injection is difficult and the research results have been largely mixed.
Reported side effects
IV oxytocin carries serious risks including uterine rupture, water intoxication with seizures, and fetal complications; intranasal research use is generally mild, with nasal irritation, headache, fatigue, and occasional mood changes being the most commonly reported issues.
Who should avoid it
Pregnant people (outside of hospital-supervised induction), those with cardiovascular disease, hyponatremia, hypersensitivity to oxytocin or chlorobutanol, and anyone on lithium or prostaglandin analogues should not use oxytocin without direct clinician supervision.
What gets monitored
Continuous clinical monitoring during IV administration. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Oxytocin Acetate or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 24 IU intranasal (6 sprays of 4 IU each, 3 per nostril) | Once or twice daily for research protocolsnonapeptide neurohormone produced in the h | intranasal | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Standard: 200-300 mcg · Low: 100 mcg · High: 400-500 mcg | Once dailycycle Duration 1-2 weeks Review Point Week 2 Notes Used in mood, anxiety, and pain research blocks. | Subcutaneous | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Half-life: about 3-6 minutes. The standard dosing for subcutaneous oxytocin is 200-300 mcg once daily. |
- Once or twice daily for research protocolsnonapeptide neurohormone produced in the h
- intranasal
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- Once dailycycle Duration 1-2 weeks Review Point Week 2 Notes Used in mood, anxiety, and pain research blocks.
- Subcutaneous
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Half-life: about 3-6 minutes. The standard dosing for subcutaneous oxytocin is 200-300 mcg once daily.
- add 2-3 mL bacteriostatic water to a 2 mg or 5 mg lyophilized vial
Common questions
Is oxytocin FDA approved?
Yes for one set of uses, no for others.
How much oxytocin is in 1 IU?
Approximately 2 micrograms of pure peptide.
What is the typical intranasal oxytocin dose used in research?
Most trials use between 10 and 72 IU per session.
Does subcutaneous oxytocin work like intranasal oxytocin?
Not for central nervous system effects.
How long does oxytocin last after reconstitution?
Typically considered usable for about 2-4 weeks when stored properly.
How do I reconstitute a 5 mg oxytocin vial?
Add 3.0 mL of bacteriostatic water.
Check 5 mg in 3 mL in the calculator →Does the largest oxytocin trial in autism show it works?
No, it found no significant difference between oxytocin and placebo.
Can oxytocin be used for anxiety, depression, or PTSD?
It is not FDA-approved for any psychiatric condition.
Sources
- 01U.S. Food and Drug Administration Oxytocin Injection, USP (synthetic) - Current FDA label (NDA 018261 / 018248). FDA Drugs@FDA (2022)
- 02U.S. Food and Drug Administration Pitocin (oxytocin injection, USP) - Prescribing information (NDA 018261). FDA Drugs@FDA (2021)
- 03Sikich L, Kolevzon A, King BH, McDougle CJ, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine (2021)
- 04Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature (2005)
- 05Quintana DS, Westlye LT, et al. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Molecular Psychiatry / PMC (2021)
- 06Martins D, Brodmann K, Veronese M, et al. Less is more : a dose-response account of intranasal oxytocin pharmacodynamics in the human brain. bioRxiv (preprint, Imperial College London team) (2021)
- 07Higgins DT, Sutton MM, et al. Plasma pharmacokinetics of intravenous and intranasal oxytocin in nonpregnant adults. Peptides / PubMed (2025)
- 08Audunsdottir K, Sartorius AM, Kang H, et al. The effects of oxytocin administration on social and routinized behaviors in autism: a preregistered systematic review and meta-analysis. Psychoneuroendocrinology (2024)
- 09Ooi YP, Weng SJ, Kossowsky J, Gerger H, Sung M. Oxytocin and Autism Spectrum Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacopsychiatry (2017)
- 10Keech B, Crowe S, Hocking DR. Intranasal oxytocin, social cognition and neurodevelopmental disorders: A meta-analysis. Psychoneuroendocrinology (2018)
- 11National Center for Biotechnology Information Oxytocin (Compound CID 439302) - structure and properties. PubChem (2026)
- 12Waltenspuhl Y, Schoppe J, Ehrenmann J, et al. Crystal structure of the human oxytocin receptor. Science Advances / bioRxiv preprint (2020)
- 13ClinicalTrials.gov (NICHD) SOARS-B: Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (NCT01944046). ClinicalTrials.gov (2021)
The reference sections above are imported from our compound knowledge base, which classes the evidence for Oxytocin Acetate as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.
Peptide bioregulator referenced for nervous system support.
Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.
Peptide bioregulator referenced for pineal support.